The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%.

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

Taken at face value, the results would suggest that the three SGLT2 inhibitors are "virtually identical," according to ...

For several decades, the prevalence of steatotic liver disease (SLD) has been steadily increasing.1 Alterations in hepatic ...

In a major setback to Boehringer Ingelheim, the Delhi High Court has upheld the maintainability of a revocation petition ...

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The drugs treat conditions such as diabetes and cancer, and seniors across the country rely on them,” President Biden said in a statement. Novo Nordisk, Merck, Boehringer Ingelheim, Pfizer and ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, including Pfizer, Novo Nordisk and GlaxoSmithKline.